| rivaroxaban / Generic mfg. |
REVNEWANTICO, NCT01210755: Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics |
|
|
| Completed | 4 | 10 | Europe | Rivaroxaban, Dabigatran, Xarelto, Pradaxa, Dabigatran; Rivaroxaban | University Hospital, Grenoble | Venous Thromboembolism | 03/11 | 06/11 | | |
NCT02054936: Evaluation of Wound Drainage After Knee or Hip Arthroplasty |
|
|
| Withdrawn | 4 | 0 | US | Rivaroxaban (Xarelto), Warfarin (Coumadin) | University of Michigan | Complications; Arthroplasty | 02/16 | 02/16 | | |
NCT01708850: Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2) |
|
|
| Completed | 4 | 70 | Canada | Rivaroxaban, Xarelto | London Health Sciences Centre | Neoplasm, Central Venous Catheter Thrombosis | 05/16 | 06/16 | | |
NCT01989845: Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer |
|
|
| Completed | 4 | 127 | RoW | Rivaroxaban, Xarelto | Seoul National University Hospital, Korean Society of Hematology Thrombosis Working Party | Rivaroxaban, Cancer-associated Thrombosis, Recurrence, Bleeding | 12/16 | 12/16 | | |
| Completed | 4 | 81 | Canada | Rivaroxaban, Xarelto | St. Joseph's Healthcare Hamilton, Heart and Stroke Foundation of Canada, Bayer, Hamilton Health Sciences Corporation, Jewish General Hospital, University of Alberta, The Ottawa Hospital, Queen Elizabeth II Health Sciences Centre | Antiphospholipid Antibody Syndrome | 09/17 | 09/17 | | |
